Allogene Therapeutics, Inc. (ALLO) vs Phathom Pharmaceuticals, Inc. (PHAT)

Allogene Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. Allogene Therapeutics, Inc. and Phathom Pharmaceuticals, Inc. are of similar size ($594.2M and $572.8M). Allogene Therapeutics, Inc. grew revenue faster over the last twelve months: 7,613.1% against 110.2%. Phathom Pharmaceuticals, Inc. has the higher net margin (−41.3% vs −3,517.4%) and the higher return on invested capital (0.00% vs −108.8%). Across the 16 metrics below, Phathom Pharmaceuticals, Inc. leads on 12 and Allogene Therapeutics, Inc. on 4.

Valuation

Metric ALLO PHAT Biotechnology median
P/E n/m n/m 7.88
P/S 115.35 2.55 11.47
P/B 1.24 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 44.66 2.49 10.73
Earnings yield (40.61%) (17.51%) (28.84%)
Free cash flow yield (18.90%) (6.03%) (23.03%)

Profitability

Metric ALLO PHAT Biotechnology median
Gross margin 100.00% 82.92% 65.16%
Operating margin (3,832.45%) (16.96%) 0.00%
Net margin (3,517.41%) (41.34%) 0.00%
Free cash flow margin (2,180.62%) (15.40%) 0.00%
Return on equity (42.39%) 26.42% (57.72%)
Return on assets (32.43%) (34.32%) (49.22%)
Return on invested capital (108.81%) 0.00% 0.00%

Growth

Metric ALLO PHAT Biotechnology median
Revenue growth (TTM) 7,613.11% 110.16% 5.64%
EPS growth (last fiscal year) 34.09% 42.72% —
Revenue growth, 5-year CAGR — — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALLO PHAT Biotechnology median
Debt to equity 0.00 (0.48) 0.00
Current ratio 10.72 1.92 4.73
Net debt to EBITDA 1.24 (0.51) 0.96

Dividend

Metric ALLO PHAT Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric ALLO PHAT Biotechnology median
Market cap 594.24m 572.78m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack